|
|
Correction, Vol. 8, No. 7
In the article, “Monitoring Antimicrobial Use and Resistance: Comparison
with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant
Enterococci” by Scott K. Fridkin et al., errors occurred in the table
on page 705. The corrected table appears below and online at http://www.cdc.gov/ncidod/eid/vol8no7/01-0465.htm.
We regret any confusion these errors may have caused.
Table. Prescribing
practice changes implemented in response to benchmark data intervention,
and mean rate of vancomycin usea before and after intervention,
50 Project ICARE ICUs, January 1996–July 1999b |
|
Vancomycin
use prescribing practice change |
No. of ICUs (%)
(n=50)
|
Vancomycin use before and after
practice change
|
p valuec
|
|
Change absent
|
Change present
|
|
|
Before
|
After
|
Before
|
After
|
|
Hospitalwided
|
22 (44)
|
|
|
|
|
|
Drug use evaluation
|
19 (38)
|
74.2
|
80.5
|
105.3
|
94.1
|
0.62
|
Redistributed HICPAC guidelines on VRE
|
9 (18)
|
79.4
|
84.6
|
116.0
|
90.6
|
0.34
|
Prior approval of vancomycin required
|
3 (6)
|
87.2
|
84.7
|
67.2
|
99.4
|
0.25
|
Unit-specificd
|
11 (22)
|
|
|
|
|
|
ICU-specific education on appropriate vancomycin
use
|
9 (18)
|
75.9
|
83.3
|
132.1
|
96.3
|
0.01
|
Removed vancomycin from surgical prophylaxis
|
3 (6)
|
82.0
|
85.9
|
149.1
|
82.2
|
0.01
|
|
aDefined daily doses per 1,000 patient-days.
bICARE, Intensive Care Antimicrobial
Resistance Epidemiology; ICU, intensive-care units; HICPAC, Healthcare
Infection Control Practices Advisory Committee; VRE, vancomycin-resistant
enterococci.
cPaired t-test.
dComponents of each major category
are not mutually exclusive, so one ICU may be represented in several
components of each category.
|
|